Heart Wall Thickness and Your Genetics

By the ExomeDNA Science Team | Last reviewed 2026-05-29

This page contains general information only. For personal health decisions, consult a qualified clinician.

Heart wall thickness — the measured depth of the left ventricular myocardium — is one of cardiology's most clinically meaningful structural parameters, and genome-wide studies now confirm that a meaningful share of population variation in this measurement is heritable. Below: the authorized gene set, the biology of adaptive versus pathological thickening, what a single large-scale GWAS found, and evidence-based actions you can take.

What is heart wall thickness?

The left ventricle is the heart's primary pumping chamber, responsible for ejecting oxygenated blood into the aorta with every heartbeat. The thickness of its muscular wall — measured by echocardiography or cardiac MRI — reflects the cumulative demand placed on that muscle over a lifetime, together with the genetic blueprint the muscle was built from.

Wall thickening is not inherently dangerous. In fact, it is the heart's primary adaptive response to increased workload. The key distinction that cardiologists draw — and that genetics is beginning to explain at a molecular level — is between two fundamentally different kinds of thickening.

Physiological hypertrophy is the heart's healthy adaptation to aerobic exercise. Endurance athletes routinely show modestly thickened walls alongside enlarged ventricular cavities, excellent ejection fractions, and normal fetal gene expression patterns. This form of remodeling is generally reversible when training stops and is associated with better — not worse — long-term outcomes.

Pathological hypertrophy is driven by chronic pressure overload (typically from sustained high blood pressure), intrinsic sarcomere mutations, or metabolic stress. Here, walls thicken without the accompanying cavity enlargement, fetal gene programs reactivate, fibrosis develops between cardiomyocytes, and systolic function eventually deteriorates. Left ventricular hypertrophy in the pathological sense is one of the strongest independent risk factors for heart failure, atrial fibrillation, and sudden cardiac death.

Genetics influence both arms of this spectrum — how strongly a heart responds to exercise-driven growth signals, and how readily it transitions into a pathological hypertrophic program under stress. Your ExomeDNA result for Heart Wall Thickness reflects common genetic variants identified by population-level genome-wide association studies (GWAS) of measured left ventricular wall thickness, not rare pathogenic mutations of the kind screened in clinical genetic testing for hypertrophic cardiomyopathy.

The genetics behind heart wall thickness

Eight authorized genes connect to the GWAS loci underlying this trait. Their biology maps cleanly onto the physiological-versus-pathological hypertrophy framework.

IGF1R (Insulin-Like Growth Factor 1 Receptor) is the receptor tyrosine kinase that transduces IGF-1 signals inside cardiomyocytes. When circulating IGF-1 rises during aerobic exercise, IGF1R activation triggers a cascade — PI3K → Akt → mTOR — that drives protein synthesis and the organized cellular growth that defines physiological hypertrophy. IGF1R-driven growth preserves systolic function, maintains normal fetal gene expression, and is reversible. Genetic variants in IGF1R that alter receptor expression or signaling efficiency influence how strongly cardiomyocytes respond to exercise-induced growth factor signals — partly determining an individual's capacity for the "athlete's heart" phenotype and adaptive cardiac remodeling.

HEY2 (Hairy/Enhancer-of-Split Related with YRPW Motif 2) operates as the Notch signaling pathway's molecular brake on hypertrophic gene expression. HEY2 is a transcriptional repressor expressed selectively in working cardiomyocytes (not in the conduction system). When Notch signaling is active — the default healthy state — HEY2 represses the GATA4, Nkx2-5, and MEF2 transcription factors that drive the hypertrophic gene program. HEY2 knockout mice develop spontaneous cardiac hypertrophy and progressive fibrosis. In humans, variants that reduce HEY2 function lower the transcriptional threshold for activating hypertrophic gene programs, meaning the heart reaches a pathological remodeling state more readily under stress. HEY2 represents a fundamentally different angle from pressure-overload mechanosensing genes: it is not about how much mechanical stress arrives at the cardiomyocyte, but about how tightly the cell's own transcriptional brake holds in response.

ATP2B1 (Plasma Membrane Ca2+-ATPase 1, PMCA1) completes the calcium cycling loop that governs both contraction and hypertrophic signaling. Calcium released from the sarcoplasmic reticulum (SR) drives each heartbeat; after contraction, it is re-sequestered into the SR by SERCA2. A third pump — PMCA1 encoded by ATP2B1 — extrudes excess calcium out of the cardiomyocyte entirely, preventing intracellular calcium accumulation. Inadequate calcium extrusion leads to calcium overload, which activates calcineurin, which in turn dephosphorylates NFAT transcription factors and drives hypertrophic gene expression. ATP2B1 variants affecting pump efficiency thus influence how susceptible cardiomyocytes are to calcium-driven hypertrophic signaling.

ALPK3 (Alpha-Kinase 3) is a cardiac- and skeletal-muscle-enriched serine/threonine kinase required for proper sarcomere assembly during heart development. Loss-of-function mutations in ALPK3 cause a severe pediatric cardiomyopathy. Common variants identified by GWAS at the ALPK3 locus are far less severe, but may influence the baseline structural set-point of the adult heart wall — the starting thickness from which exercise and pressure-related remodeling proceed.

CASQ2 (Calsequestrin 2) is the SR calcium buffer that modulates the calcium signal amplitude available for each contraction. Alongside ATP2B1, CASQ2 represents the calcium-handling axis of wall thickness genetics. Pathogenic CASQ2 mutations cause catecholaminergic polymorphic ventricular tachycardia; common variants contribute to SR calcium dynamics that feed into calcineurin-NFAT hypertrophic signaling.

CDKN1A (p21/CIP1) encodes a cyclin-dependent kinase inhibitor that enforces cell cycle arrest in terminally differentiated cardiomyocytes. In the post-mitotic heart, p21 may influence the balance between hypertrophic growth responses (enlarging individual cells) and compensatory proliferation-like signaling. Its presence among GWAS-identified loci underscores that cardiomyocyte fate decisions are genetically tuned.

CELF1 (CUGBP Elav-Like Family Member 1) is an RNA-binding protein upregulated in heart failure that promotes pathological alternative splicing of titin — the giant sarcomere spring protein — and cardiac troponin isoforms. CELF1-mediated splicing shifts produce stiffer sarcomeres that contribute to diastolic dysfunction and pathological remodeling. Genetic variation at the CELF1 locus affects how readily mRNA processing shifts toward pathological isoforms under stress.

MAPRE2 (Microtubule End-Binding Protein EB2) is involved in microtubule dynamics within cardiomyocytes. Microtubule densification — the proliferation of stable microtubules within cardiomyocytes — is a hallmark of pathological hypertrophy and contributes to the increased mechanical stiffness seen in hypertrophied hearts. MAPRE2 variants affecting microtubule end-binding behavior may modulate this structural remodeling axis.

What the research says

Research base: Moderate. A single large-scale GWAS provides the primary evidence base for this trait's genetic architecture.

Tadros et al. (2025, PMID 39966646) conducted genome-wide association analyses of left ventricular wall thickness (mean) in a large population cohort, identifying novel genetic loci and elucidating mechanisms contributing to cardiac structure. This study, among the most powered ever conducted for cardiac imaging phenotypes, confirmed that population-level variation in left ventricular wall thickness has a significant heritable component and mapped multiple independent signals.

Key quantitative observations from the broader cardiac GWAS literature:

Heritability estimates for left ventricular wall thickness from twin and genomic studies typically range from 30–60%, indicating that a substantial fraction of population variation has a genetic basis.
Pathological left ventricular hypertrophy (LVH) is present in approximately 15–20% of adults with long-standing hypertension and is associated with a roughly 2–4-fold increase in major adverse cardiovascular event risk independent of blood pressure levels.
The athlete's heart — physiological hypertrophy — is observed in up to 50% of competitive endurance athletes and is generally benign, with wall thicknesses that typically remain below the clinical diagnostic threshold for hypertrophic cardiomyopathy (HCM) of 15 mm.
Calcineurin-NFAT signaling, the downstream effector of calcium overload (ATP2B1/CASQ2 axis), is sufficient to drive pathological hypertrophy in animal models and is the target of pharmacological interest in heart failure prevention.

Authorized gene-level signals by magnitude ranking (from GWAS-derived locus-to-gene analysis):

CASQ2 — L2G score 0.876 (high confidence locus)
ALPK3 — cardiac kinase; sarcomere assembly
IGF1R — physiological hypertrophy axis
HEY2 — Notch-driven transcriptional brake
ATP2B1 — calcium extrusion, calcineurin gating
CELF1 — pathological splicing
CDKN1A — cardiomyocyte cycle arrest
MAPRE2 — microtubule densification

The convergence of these loci on calcium handling, transcriptional regulation, and growth factor signaling reflects the molecular complexity of a phenotype that sits at the intersection of adaptive physiology and pathological remodeling.

How heart wall thickness affects you

Left ventricular wall thickness is a structural measurement — what it means for you depends heavily on context: blood pressure history, exercise habits, family history, and the absolute measured value.

When thickening is adaptive: Moderate wall thickening in a healthy, exercising individual with normal blood pressure and good systolic function is typically a favorable marker of cardiac adaptation. Athletes who carry variants that amplify IGF1R-mediated growth factor signaling may develop a more pronounced but still physiological athlete's heart.

When thickening signals risk: In the context of chronically elevated blood pressure, greater genetic propensity for wall thickening — especially through the HEY2 (lower braking capacity) or ATP2B1/CASQ2 (calcium overload susceptibility) axes — accelerates the transition from adaptive to pathological hypertrophy. Pathological LVH increases stiffness, impairs filling (diastolic dysfunction), and sets the stage for atrial fibrillation, heart failure with preserved ejection fraction (HFpEF), and malignant arrhythmia.

Hypertrophic cardiomyopathy (HCM) note: HCM is caused primarily by rare pathogenic variants in sarcomere genes (MYH7, MYBPC3, etc.) and is not what this GWAS trait measures. ExomeDNA's Heart Wall Thickness result reflects common variants influencing population-level variation, not rare monogenic cardiomyopathy risk. Individuals with a family history of HCM should discuss dedicated clinical genetic testing with their cardiologist.

Sex and age interactions: Wall thickness increases modestly with age in the general population, and men show somewhat greater mean wall thickness than women at population level — partly reflecting body size and partly reflecting androgen-related hypertrophic signaling differences. A higher genetic propensity score compounds on top of these background trends.

Working with your heart wall thickness result

The following actions are numbered in order of evidence strength and practical priority.

Control blood pressure. This is the single most powerful modifiable driver of pathological wall thickening. Target systolic blood pressure below 130 mmHg, consistent with major cardiology guidelines for individuals with hypertension or high cardiovascular risk. Even modest chronic blood pressure elevation of 10–15 mmHg over years meaningfully accelerates LVH progression.
Maintain regular aerobic exercise. Aerobic training activates IGF1R-mediated physiological hypertrophy, which is structurally distinct from pathological thickening. Regular moderate-to-vigorous aerobic exercise (≥150 minutes/week) is associated with favorable cardiac remodeling, improved diastolic function, and reduced risk of heart failure — even in individuals with genetically higher baseline wall thickness.
Reduce dietary sodium. Sodium restriction directly lowers blood pressure and reduces the pressure-overload signal driving pathological wall thickening. The 2024 American Heart Association guidelines recommend less than 2,300 mg/day, with 1,500 mg/day as a target for individuals with hypertension.
Avoid anabolic androgenic steroids. Exogenous androgens drive pathological cardiac remodeling — concentric LVH with impaired diastolic function — through mechanisms distinct from the IGF1R physiological pathway. This is especially relevant for individuals already carrying genetic variants that reduce the molecular brakes on hypertrophy.
Discuss echocardiographic monitoring with your clinician for those with a family history of hypertrophic cardiomyopathy or unexplained sudden cardiac death. Your ExomeDNA result is not a substitute for clinical evaluation, but it can inform a conversation about the appropriate monitoring interval.
Consider optimizing sleep and stress management. Chronic sympathetic nervous system activation raises blood pressure and cortisol, both of which promote pathological hypertrophic signaling. Sleep-disordered breathing (obstructive sleep apnea) is an underrecognized driver of LVH, particularly in individuals with genetic susceptibility.
Maintain a heart-healthy dietary pattern. The DASH diet and Mediterranean diet patterns are associated with blood pressure reduction and reduced LVH progression in prospective studies.

Heart wall thickness sits within a network of related cardiac structure and function traits, each with its own genetic architecture.

Sibling traits (Heart Rhythm & Structure category):

Heart Rate Variability (RMSSD) Genetics (TRAIT_070437) — autonomic modulation of heart rhythm; shares calcium-handling biology with ATP2B1/CASQ2 axis.
Resting Heart Rate Genetics (TRAIT_048980) — chronotropic set-point; influenced by HCN4 and overlapping ion channel biology.
Heart Rate Response to Exercise (TRAIT_064055) — how the heart accelerates during physical activity; shares exercise-adaptation biology with the IGF1R axis.

Cross-category links:

High Blood Pressure Genetics (TRAIT_048866) — the primary environmental driver of pathological wall thickening; genetic risk in both traits compounds cardiovascular risk significantly.
Cardiovascular Disease Risk Genetics (TRAIT_057993) — downstream outcome trait; wall thickness is one structural mediator of genetic cardiovascular disease risk.

**Key

IGF1R — the growth factor receptor driving physiological hypertrophy; central to adaptive cardiac remodeling and the athlete's heart.
HEY2 — the Notch-activated transcriptional brake; variants here determine how readily the hypertrophic program activates.

Frequently asked questions

What does a "higher" Heart Wall Thickness result from ExomeDNA mean? Your genetic variants associated with this trait point toward a modestly greater population-level tendency toward left ventricular wall thickening. Because the trait is classified as "higher is detrimental," this suggests a somewhat lower threshold for wall thickening under conditions of blood pressure stress. It does not mean your heart is currently thick or that cardiac problems will necessarily develop.

Is this the same as hypertrophic cardiomyopathy (HCM)? No. HCM is a distinct condition caused by rare pathogenic variants in sarcomere genes, primarily MYH7 and MYBPC3. ExomeDNA's Heart Wall Thickness result is derived from common GWAS variants that explain modest differences in wall thickness across a healthy population. For those with a family history of HCM, consult a cardiologist for dedicated clinical genetic testing.

Can I reverse wall thickening through lifestyle changes? Pathological LVH driven by high blood pressure can partially regress with sustained blood pressure control, particularly with ACE inhibitors, ARBs, or aldosterone antagonists. Exercise-induced physiological thickening typically recedes when training volume decreases. The reversibility of genetically influenced baseline thickening is less well established.

Why are IGF1R and HEY2 highlighted for this trait when they weren't emphasized for the related inferoseptal wall thickness trait? The mean left ventricular wall thickness phenotype captures the global adaptive-versus-pathological spectrum more broadly. The IGF1R axis (physiological, exercise-driven, PI3K/Akt/mTOR) and HEY2 (Notch transcriptional braking) represent mechanistically distinct from the PTK2/FAK mechanosensing and MYO18B sarcomere assembly pathways more prominent in other cardiac structural subtypes. Different GWAS phenotypes resolve different biological axes even within the same organ.

What should I tell my doctor about this result? You can share that you carry common genetic variants associated with modest population-level tendencies in left ventricular wall thickness. This may be useful context if your clinician is already monitoring your blood pressure, discussing cardiac imaging, or evaluating your cardiovascular risk. It is not a clinical assessment and does not replace echocardiographic measurement.

How confident should I be in this result? The confidence tier for this trait is moderate. The finding is supported by a large-scale 2025 GWAS (Tadros et al., PMID 39966646) identifying novel loci for left ventricular wall thickness. Common-variant polygenic signals for cardiac structural traits explain a meaningful but still partial share of heritable variation; rare variants and environmental factors contribute substantially.

References: Tadros R et al. (2025). Large-scale genome-wide association analyses identify novel genetic loci and mechanisms for left ventricular wall thickness. PMID 39966646.

ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.

Browse all traits →